Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPTLC1 | O15269 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577483 | 0.85 | P2RX7 (0.40) | P2RX7BRD4CREBBPKCNH2SLC6A7 | |
| SCHEMBL29844034 | 0.83 | KCNK3 (0.56) | KCNK3 | |
| SCHEMBL28818558 | 0.78 | KCNK3 (0.48) | P2RX7KCNK3BRD4CREBBPSPTLC1 | |
| SCHEMBL24529929 | 0.77 | MEN1 (0.58) | SLC6A7MEN1HPGDTSHRKMT2A | |
| SCHEMBL23577559 | 0.74 | USP7 (0.38) | KCNH2SLC6A7MEN1HPGDTSHR | |
| SCHEMBL29844006 | 0.74 | MEN1 (0.55) | MEN1HPGDTSHRKMT2AEPHX2 | |
| SCHEMBL29844211 | 0.74 | CTSS (0.46) | P2RX7KCNK3BRD4CREBBPSPTLC1 | |
| SCHEMBL29844016 | 0.74 | NAMPT (0.44) | KCNH2SLC6A7MEN1HPGDTSHR | |
| SCHEMBL23577519 | 0.73 | EPHX2 (0.39) | KCNH2SLC6A7MEN1HPGDTSHR | |
| SCHEMBL23605612 | 0.73 | HPGD (0.42) | SLC6A7MEN1HPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | claimed |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | P2RX7 4322/4885KCNK3 2642/4885BRD4 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.